Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Withdrawn 1Recruiting 1Enrolling by invitation 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 4Gastrointestinal 3Dermatologic 3Gynecologic 2Sarcoma 1Head & Neck 1

Conditions

Melanoma 2Skin Neoplasms 1Melanoma, Cutaneous Malignant 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Specimen Handling 49Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Electrochemotherapy × Dermatologic × Clear all
NCT06388252 2026-02-19

Electrochemotherapy Changes in Tumor Microenvironment of Cutaneous and Subcutaneous Metastases in Melanoma Patients

Institute of Oncology Ljubljana

Phase NA Enrolling by invitation
10 enrolled
Dermatologic

Melanoma, Cutaneous Malignant

NCT07404605 2026-02-19

Electrochemotherapy-Induced Changes in Tumor Microenvironment in Cutaneous Melanoma

Institute of Oncology Ljubljana

Phase NA Recruiting
150 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

European Institute of Oncology

Phase 2 Withdrawn
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡